Drug intelligence / Profile preview

Amoxicillin + Netilmicin

Development stage
Unknown
Lead developer
US Antibiotics
Modality
Small Molecules
Administration
Intravenous, Intramuscular
01

Overview

Amoxicillin + netilmicin is a combination of two antibiotics used to treat serious bacterial infections, particularly those caused by resistant organisms. Amoxicillin is a beta-lactam antibiotic that inhibits penicillin-binding proteins, disrupting bacterial cell wall synthesis and leading to cell lysis and death. Netilmicin is an aminoglycoside antibiotic that binds irreversibly to the 30S ribosomal subunit of bacteria, causing misreading of mRNA and inhibition of protein synthesis, which results in bactericidal activity. The combination may be used for synergistic effects against certain pathogens such as Enterococcus faecalis; however, studies have shown mixed results regarding enhanced efficacy over monotherapy with amoxicillin alone[1][2]. Both drugs are administered parenterally for severe infections including bacteremia, septicemia, respiratory tract infections, skin and soft tissue infections[3][5][6].

Brand names
vectacin
Other names
1-N-aethylsisomicinnetilyn
02

Targets

PBP (Penicillin-binding protein family)30S A-site (Bacterial ribosomal 30S A-site)

Beyond the preview

Go deeper on Amoxicillin + Netilmicin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amoxicillin + Netilmicin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call